Abstract Number: 489 • 2012 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Anti-TNF Medications Among Older and Disabled Rheumatoid Arthritis Patients in the U.S. Medicare Population
Background/Purpose: Evaluating the real world effectiveness of biologic DMARDs in rheumatoid arthritis (RA) patients using administrative claims data has previously not been feasible due to…Abstract Number: 450 • 2012 ACR/ARHP Annual Meeting
Late Onset Neutropenia After Rituximab Treatment for Rheumatological Conditions
Background/Purpose: Rituximab is a monoclonal chimeric antibody targeting the CD20 on the surface of normal and abnormal maturing B cells. Late onset neutropenia (LON) is…Abstract Number: 451 • 2012 ACR/ARHP Annual Meeting
Pilot Study of Stimulation of the Cholinergic Anti-Inflammatory Pathway with an Implantable Vagus Nerve Stimulation Device in Patients with Rheumatoid Arthritis
Background/Purpose: The inflammatory reflex regulates innate and adaptive immunity (Andersson O, Tracey K, Annu. Rev. Immunol. 2012; 30:313). Activation of its efferent arm (the Cholinergic…Abstract Number: 452 • 2012 ACR/ARHP Annual Meeting
Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose
Background/Purpose: The optimal dose of corticosteroid to be used in intraarticular injection is not well established. The objective of this study is to compare the…Abstract Number: 453 • 2012 ACR/ARHP Annual Meeting
Fish Oil in Rheumatoid Arthritis: A Randomised, Double Blind Trial Comparing High Dose with Low Dose
Background/Purpose: The symptomatic benefit and NSAID-sparing effects of fish oil (FO) in RA are well known but effects on disease outcomes are less well established,…Abstract Number: 454 • 2012 ACR/ARHP Annual Meeting
Long-Term Efficacy of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Previously Methotrexate Naive or Methotrexate Free for 6 Months
Background/Purpose: Treatment with tocilizumab (TCZ) monotherapy has been studied in 3 randomized clinical trials: AMBITION,1 ACT-RAY,2 and ADACTA.3 AMBITION1 was the first trial to demonstrate…Abstract Number: 455 • 2012 ACR/ARHP Annual Meeting
Lack of Additive Benefits of Concomitant Methotrexate Use to Tocilizumab Monotherapy for Rheumatoid Arthritis in Daily Clinical Practice
Background/Purpose: To explore the benefit of concomitant use of methotrexate (MTX) for the effectiveness of TCZ in rheumatoid arthritis (RA) patients in daily clinical practice.…Abstract Number: 456 • 2012 ACR/ARHP Annual Meeting
Factors Influencing Choice of Rituximab Versus an Alternative Tumor Necrosis Factor Inhibitor Following Tumor Necrosis Factor Inhibitor Failure in Patients with Rheumatoid Arthritis: Sub-Analysis of a Global, Observational Comparative Effectiveness Study
Background/Purpose: SWITCH-RA is a global, observational study evaluating the effectiveness of switching to an alternative TNFi or rituximab (RTX) following initial TNFi failure in patients…Abstract Number: 457 • 2012 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) may interfere with bone remodelling. Inflammation mediators such as TNF-α stimulate osteoclast formation which favors bone destruction. Small…Abstract Number: 458 • 2012 ACR/ARHP Annual Meeting
Better Retention RATE At 5 YEARS of ANTI-TNF Agents USED in Conjonction with Methotrexate Over Time in Patients with Rheumatoid Arthritis: REAL-Life DATA From Rhumadata Computarized Database
Background/Purpose: Anti-TNF agents have been in used in Canada for the last ten years. Although a vast body of clinical experience has been accumulated since…Abstract Number: 459 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Rituximab: 10-Year Follow-up in the Rheumatoid Arthritis Global Clinical Trial Program
Background/Purpose: This analysis evaluated the long-term safety of rituximab (RTX) in RA patients (pts) in a global clinical trial program. Methods: Pooled observed case analysis…Abstract Number: 460 • 2012 ACR/ARHP Annual Meeting
Real-World Efficacy and Safety of Abatacept Treatment for Rheumatoid Arthritis: 12-Month Interim Analysis of the Action Study
Background/Purpose: Randomized controlled trials (RCTs) of abatacept (ABA) in patients (pts) with RA have demonstrated sustained, long-term efficacy, high pt retention, and consistent safety.1 Data…Abstract Number: 461 • 2012 ACR/ARHP Annual Meeting
Patterns of Tocilizumab Use, and Dosing Among Patients with Rheumatoid Arthritis in the Clinical Practice. Preliminary Analyses of ACT-Life Study
Background/Purpose: Currently, the available evidence about tocilizumab (TCZ) use for the treatment of rheumatoid arthritis (RA) in daily clinical practice is scarce. This study was…Abstract Number: 462 • 2012 ACR/ARHP Annual Meeting
Subcutaneous Abatacept: Long-Term Data From the Acquire Trial
Background/Purpose: The Abatacept (ABA) Comparison of Sub[QU]cutaneous (SC) versus Intravenous (IV) in Inadequate Responders to MethotrexatE (MTX) (ACQUIRE) study showed comparable efficacy and safety of…Abstract Number: 463 • 2012 ACR/ARHP Annual Meeting
Drug Survival, Efficacy and Predictors for Survival On Tocilizumab in Real-Life Patients with Rheumatoid Arthritis; Results From the Swedish Biologics Register
Background/Purpose: To evaluate drug survival, clinical response and predictors for drug survival for tocilizumab in patients with rheumatoid arthritis (RA) with inadequate response and/or adverse…